Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain

Brain

Volumn 138, Issue 6, 2015, Pages 1642-1657

  Roberts, Rosalind F ^a   Wade Martins, Richard ^a   Alegre Abarrategui, Javier ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alpha synuclein; Oligomers; Parkinson's disease; Pathology

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; PROTEINASE K;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BIOASSAY; BRAIN; BRAIN DAMAGE; BRAIN REGION; BRAIN TISSUE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; FIBER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; MALE; MEDULLA OBLONGATA; NEUROANATOMY; NEUROPATHOLOGY; OLIGOMERIZATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERIKARYON; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROXIMITY LIGATION ASSAY; RETICULAR FORMATION; SHY DRAGER SYNDROME; TISSUE SECTION; CASE CONTROL STUDY; CHEMISTRY; EARLY DIAGNOSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELL LINE; METABOLISM; NERVE CELL; PATHOLOGY; POLYMERIZATION; VALIDATION STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GYRUS CINGULI; HEK293 CELLS; HUMANS; LEWY BODIES; MALE; NEURONS; PARKINSON DISEASE; POLYMERIZATION; RETICULAR FORMATION;

EID: 84938704559     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv040     Document Type: Article

References (70)

1. Apetri MM, Maiti NC, Zagorski MG, Carey PR, Anderson VE Secondary structure of alpha-synuclein oligomers: characterization by raman and atomic force microscopy. J Mol Biol 2006; 355: 63-71
2. Arima K, Ueda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, et al. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998; 808: 93-100
3. Baan B, Pardali E, ten Dijke P, van Dam H. In situ proximity ligation detection of c-Jun/AP-1 dimers reveals increased levels of c-Jun/Fra1 complexes in aggressive breast cancer cell lines in vitro and in vivo Mol Cell Proteomics 2010; 9: 1982-90
4. Bartels T, Choi JG, Selkoe DJ. Alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107-10
5. Bosco DA, Lavoie MJ, Petsko GA, Ringe D. Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis Cold Spring Harb Perspect Biol 2011; 3: a007500
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
7. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-7
8. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507-11
9. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267-98
10. Celej MS, Sarroukh R, Goormaghtigh E, Fidelio GD, Ruysschaert JM, Raussens V. Toxic prefibrillar alpha-synuclein amyloid oligomers adopt a distinctive antiparallel beta-sheet structure. Biochem J 2012; 443: 719-26
11. Chen L, Jin J, Davis J, Zhou Y, Wang Y, Liu J, et al. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun 2007; 356: 548-53
12. Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, et al. Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA 2013; 110: 4087-92
13. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 2012; 32: 3301-5
14. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, et al Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 2012; 149: 1048-59
15. Czlapinski JL, Schelle MW, Miller LW, Laughlin ST, Kohler JJ, Cornish VW, et al. Conditional glycosylation in eukaryotic cells using a biocompatible chemical inducer of dimerization. J Am Chem Soc 2008; 130: 13186-7
16. Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN Relationships between lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol 1992; 83: 525-9
17. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007; 27: 9220-32
18. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al Inclusion formation and neuronal cell death through neuron-toneuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009; 106: 13010-5
19. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-25
20. Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome Neurobiol Aging 2010; 31: 953-68
21. Forloni G. Neurotoxicity of beta-amyloid and prion peptides. Curr Opin Neurol 1996; 9: 492-500
22. Gomez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining Acta Neuropathol 2000; 99: 352-7
23. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 2002; 277: 48984-92
24. Gruber S, Arumugam P, Katou Y, Kuglitsch D, Helmhart W, Shirahige K, et al. Evidence that loading of cohesin onto chromosomes involves opening of its SMC hinge. Cell 2006; 127: 523-37
25. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, et al alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-25
26. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14: 467-75
27. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345: 27-32
28. Kamali-Moghaddam M, Pettersson FE, Wu D, Englund H, Darmanis S, Lord A, et al. Sensitive detection of Abeta protofibrils by proximity ligation-relevance for Alzheimer's disease. BMC Neurosci 2010; 11: 124
29. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, Uchihara T. Pale neurites, premature alpha-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol 2012; 22: 67-78
30. Katsuse O, Iseki E, Marui W, Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003; 211: 29-35
31. Kim-Han JS, Antenor-Dorsey JA, O'Malley KL. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci 2011; 31: 7212-21
32. Kim HY, Cho MK, Kumar A, Maier E, Siebenhaar C, Becker S, et al Structural properties of pore-forming oligomers of alpha-synuclein J Am Chem Soc 2009; 131: 17482-9
33. Kosaka K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol 1978; 42: 127-34
34. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405-10
35. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, et al. Oxidative dimer formation is the critical ratelimiting step for Parkinson's disease alpha-synuclein fibrillogenesis Biochemistry 2003; 42: 829-37
36. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62 J Neuropathol Exp Neurol 2003; 62: 1241-53
37. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 2002a; 418: 291
38. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, et al Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002b; 322: 1089-102
39. Lee HJ, Lee SJ. Characterization of cytoplasmic alpha-synuclein aggregates Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 2002; 277: 48976-83
40. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinsonlike neurodegeneration in nontransgenic mice. Science 2012a; 338: 949-53
41. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012b; 209: 975-86
42. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013; 136 (Pt 4): 1128-38
43. McKeith IG. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 2000; 18: 865-902
44. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002; 277: 19213-9
45. Muchowski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 2002; 35: 9-12
46. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homoand heterodimers. Mol Cell Biol 1999; 19: 6845-57
47. Nakata Y, Yasuda T, Fukaya M, Yamamori S, Itakura M, Nihira T, et al. Accumulation of alpha-synuclein triggered by presynaptic dysfunction J Neurosci 2012; 32: 17186-96
48. Nasstrom T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A, et al. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med 2011; 50: 428-37
49. Neumann M, Muller V, Kretzschmar HA, Haass C, Kahle PJ Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 2004; 63: 1225-35
50. Nordengrahn A, Gustafsdottir SM, Ebert K, Reid SM, King DP, Ferris NP, et al. Evaluation of a novel proximity ligation assay for the sensitive and rapid detection of foot-and-mouth disease virus Vet Microbiol 2008; 127: 227-36
51. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008; 3: e1867
52. Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and neurotoxicity of recombinant alpha-synuclein aggregates initiated by dimerization. Mol Neurodegener 2013; 8: 5
53. Ryan BJ, Lourenco-Venda L, Crabtree MJ, Hale AB, Channon KM, Wade-Martins R. Alpha-synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radic Biol Med 2013; 67: 58-68
54. Schlingemann J, Leijon M, Yacoub A, Schlingemann H, Zohari S, Matyi-Toth A, et al. Novel means of viral antigen identification: improved detection of avian influenza viruses by proximity ligation J Virol Methods 2010; 163: 116-22
55. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120: 131-43
56. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloidlike cross-beta conformation. Proc Natl Acad Sci USA 2000; 97: 4897-902
57. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000
58. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008; 65: 184-9
59. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40
60. Tavoosidana G, Ronquist G, Darmanis S, Yan J, Carlsson L, Wu D, et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci USA 2011; 108: 8809-14
61. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, et al. CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 2008; 283: 17962-8
62. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278: 44405-11
63. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 2001; 40: 7812-9
64. Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, et al. A soluble alpha-synuclein construct forms a dynamic tetramer Proc Natl Acad Sci USA 2011; 108: 17797-802
65. Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM, et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics 2010; 7: 401-9
66. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011; 108: 4194-9
67. Wittig I, Schagger H. Advantages and limitations of clear-native PAGE. Proteomics 2005; 5: 4338-46
68. Yung HW, Charnock-Jones DS, Burton GJ. Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 2011; 6: e17894
69. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73
70. Zhang NY, Tang Z, Liu CW. alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis J Biol Chem 2008; 283: 20288-98